Cabaletta Bio, Inc. develops targeted cell therapies designed to provide deep and durable treatments for autoimmune diseases. The company's proprietary CABA platform encompasses two complementary strategies: CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) and CAART (Chimeric AutoAntibody Receptor T cells). Its lead product candidate, rese-cel, is a fully human CD19-CAR T cell therapy currently being evaluated in the RESET clinical program across multiple indications, including lupus, myositis, systemic sclerosis, and myasthenia gravis. The company collaborates with leading academic institutions, including the University of Pennsylvania, to advance its pipeline. As a clinical-stage entity, Cabaletta Bio does not yet generate product revenue and focuses entirely on advancing its investigational therapies through clinical trials.
